Cargando…
Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
BACKGROUND: The best possible treatment of metastatic high grade large duodenal GIST is controversial. Surgery (with or without segmental organ resection) remains the principal treatment for primary and recurrent GIST. However, patients with advanced duodenal GIST have a high risk of early tumour re...
Autores principales: | Mohiuddin, Kamran, Nizami, Saira, Munir, Asma, Memon, Breda, Memon, Muhammed A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851968/ https://www.ncbi.nlm.nih.gov/pubmed/17391535 http://dx.doi.org/10.1186/1477-7800-4-9 |
Ejemplares similares
-
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017) -
Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018) -
Delayed Duodenal Hematoma and Pancreatitis from a Seatbelt Injury
por: DeAmbrosis, Katherine, et al.
Publicado: (2011) -
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016) -
Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)